Evidence map›Paper›PMID 42334452›Full record

ArticleeLife2026

Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.

Yi Lin, Benjamin Liou, Venette Fannin, Stuart Adler, Christopher N Mayhew, Jason E Hammonds, Yueh-Chiang Hu, Jason Tchieu, Wujuan Zhang, Xueheng Zhao and 6 more

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Yi LinDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.ORCID https://orcid.org/0000-0001-8209-1185
Benjamin LiouDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.ORCID https://orcid.org/0000-0003-4848-3964
Venette FanninDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
Stuart AdlerDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
Christopher N MayhewDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
Jason E HammondsDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
Yueh-Chiang HuDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
Jason TchieuDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.ORCID https://orcid.org/0000-0002-9793-9836
Wujuan ZhangDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
Xueheng ZhaoDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
Rebecca L BeresDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.
Kenneth D R SetchellDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.
Ahmet KaynakDivision of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati, College of Medicine, Cincinnati, United States.ORCID https://orcid.org/0000-0001-6551-1125
Xiaoyang QiDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, United States.ORCID https://orcid.org/0000-0001-5363-1760
Ricardo A FeldmanDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, United States.ORCID https://orcid.org/0000-0001-6090-0439
Ying SunDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States.ORCID https://orcid.org/0000-0002-2979-4735

Funding

Progranulin: A Novel Gene in Gaucher DiseasesR01NS103931 · NINDS · YALE UNIVERSITY · PI Chuanju Liu, Ying Sun · 2017 to 2026
$4.3M
Systemic Enzyme Delivery by a Brain Targeted SapC-DOPS Nanocarrier for Treatment of Neuronopathic Gaucher DiseaseR01NS138309 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI XIAOYANG QI, Ying Sun · 2024 to 2026
$1.9M
Brain organoid modeling of Gaucher disease for identification of pathogenic pathways and therapy developmentR21HD102788 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI SUN, YING · 2020 to 2021
$437k
Cincinnati Children's Hospital Medical Center Center of Pediatric Genomics AwardCincinnati Children's Hospital Medical Center Research Innovation Pilot Funding Program AwardNational Institute of Health R01NS103931National Institute of Health R21OD033660NICHD NIH HHS R21 HD102788NICHD NIH HHS R21HD1027881NIH HHS 2UL1TR001425-05A1, CHMC-CTSA 00003827NINDS NIH HHS R01 NS103931NINDS NIH HHS R01 NS138309NINDS NIH HHS R01NS138309
6 · The paper itself

Abstract

Neuronopathic Gaucher disease (nGD) is a lysosomal storage disorder caused by

Indexed as

CRISPR-Cas SystemsGaucher DiseaseGlucosylceramidaseMesencephalonOrganoidsDopaminergic NeuronsHumansInduced Pluripotent Stem CellsMutationPhenotypeGBA protein, humanGlucosylceramidasedopaminergic neuronsgene editinghumaniPSC disease modelinglipid metabolismmidbrain-like organoidsneuronopathic Gaucher diseaseneuroscienceregenerative medicinestem cells

Identifiers

PMID42334452
PMCPMC13290227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.